A shocking revelation has emerged from a startup pharmacy in Kirkland, Washington, where whistleblowers have exposed a dangerous practice. Unlicensed workers, recruited from hardware store parking lots, were handling prescription medications, including GLP-1 weight-loss drugs, with potentially dire consequences for patients.
Patient Safety at Risk: Unlicensed Workers in a Pharmacy?
In a quiet business park, a pharmacy startup, Aequita, was struggling to meet the demand for affordable weight-loss medications. But here's where it gets controversial: the company's pursuit of profit led to a series of alarming shortcuts, as revealed by multiple whistleblowers and internal videos.
Aequita, a subsidiary of Mochi Health, manufactured generic versions of popular GLP-1 drugs like Ozempic and Mounjaro, offering them at a fraction of the cost. As orders flooded in, the small Kirkland facility faced a manpower crisis. The operations manager, James Lindsay, took a risky approach, recruiting day laborers from Home Depot and Lowe's parking lots to fill the staffing gap.
Unqualified Workers in Restricted Areas
Surveillance footage obtained by state investigators paints a disturbing picture. In one video, a day laborer, with no state licensing, opens a refrigerator containing GLP-1 medications bearing patient names - a clear violation of state law. The temporary worker sorts through the medications while Lindsay walks by, seemingly unbothered. Other videos show unlicensed laborers packing medications and labeling boxes for shipment, tasks legally reserved for licensed pharmacy assistants.
Paul Meyers, Aequita's former lab manager and a whistleblower, shared his concerns: "They were there pretty much all the time. Most days that I was there, they were there."
Maximizing Output, Minimizing Safety
Multiple whistleblowers reported relentless pressure to maximize output, with little regard for safety and quality control. Meyers confirmed, "Making money was the primary focus." The pressures, according to employees, came from executives at Mochi Health, Aequita's parent company.
The Washington State Department of Health (DOH) assigned investigators to the case, conducting inspections at the Kirkland facility. Inspectors found numerous violations and placed restrictions on Aequita's drug compounding license, but the nature of these restrictions remains unclear.
A DOH spokesperson commented, "Aequita addressed the deficiencies, so they can operate for now." However, the investigation is ongoing, and further details are unavailable.
Consequences for Patients
The consequences of these shortcuts became evident to customers. Mochi Health clients posted photos online, showing contamination in their medication vials - defects that trained pharmacists should have caught. Meyers confirmed, "Very frequently, the pharmacists complained about debris being in the vials."
Cost-Cutting Measures: 'Glassgate' and 'Otter Pops'
Whistleblowers dubbed one cost-cutting measure "Glassgate." Instead of purchasing medical-grade vials, Aequita ordered cheaper glassware from Alibaba, leading to vials "breaking and shattering" during handling and shipment. Another shortcut involved using children's popsicles, "Otter Pops," to keep medications cold during transit, instead of medical-grade ice packs. This practice was discontinued after numerous customer complaints.
Some customers claim Mochi medications made them seriously ill. Shawn Rose of Chicago documented his experience on TikTok after an injection of Mochi's GLP-1 drug left him violently sick. He visited the hospital four times and shared his concern: "At one point, they told me if I hadn't come in when I did, I probably would have died."
Company Silence and Growing Concerns
When KING 5 Investigators visited the Kirkland facility, they were met with silence. A man named "Dante" answered the door but refused to discuss the allegations. Founder Myra Ahmad, a University of Washington medical school dropout, also remained silent, with no response from her team.
Whistleblower Paul Meyers, who worked for Mochi for only four months, expressed deep regret: "I do regret working for that company. My effort there could have hurt people, and that's not what I want to do."
The Washington State Department of Health continues its investigation into Aequita's practices, highlighting growing concerns about the unregulated market for compounded weight-loss drugs. The promise of affordable alternatives to expensive brand-name medications must not compromise pharmaceutical safety standards.
If you have had issues with Mochi and its delivery weight-loss medications, contact the KING 5 Investigators at investigators@king.com.
